Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
AstraZeneca
Colorcon
Moodys

Last Updated: November 29, 2022

Desvenlafaxine succinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for desvenlafaxine succinate and what is the scope of freedom to operate?

Desvenlafaxine succinate is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Hikma, Intellipharmaceutics, Lupin Ltd, Mylan, Rubicon, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are eleven drug master file entries for desvenlafaxine succinate. Eighteen suppliers are listed for this compound.

Recent Clinical Trials for desvenlafaxine succinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Seoul National University HospitalPhase 4
Seoul National University Bundang HospitalPhase 4

See all desvenlafaxine succinate clinical trials

Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate
Paragraph IV (Patent) Challenges for DESVENLAFAXINE SUCCINATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PRISTIQ Extended-release Tablets desvenlafaxine succinate 25 mg 021992 1 2015-05-08
PRISTIQ Extended-release Tablets desvenlafaxine succinate 50 mg and 100 mg 021992 12 2012-02-29

US Patents and Regulatory Information for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204095-002 Jun 29, 2015 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Yichang Humanwell DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 210014-003 Oct 13, 2020 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Yichang Humanwell DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 210014-002 Oct 1, 2018 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for desvenlafaxine succinate

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 0059851 See Plans and Pricing
Peru 20020877 SUCCINATO DE O-DESMETIL-VENLAFAXINA See Plans and Pricing
Denmark 1466889 See Plans and Pricing
Canada 2368083 See Plans and Pricing
European Patent Office 1165487 See Plans and Pricing
Germany 60039132 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Boehringer Ingelheim
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.